文献速递血液净化与透析

腹膜透析患者新发糖代谢紊乱:系统评价与荟萃分析

New-onset glucose disorders in peritoneal dialysis patients: a meta-analysis and systematic review.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

腹膜透析与血液透析的新发糖尿病风险无显著差异(RR 0.99,95%CI 0.69-1.40;P=0.94)。新发糖尿病与腹膜透析患者死亡风险增加相关(HR 1.06,95%CI 1.01-1.44;P<0.001)。

要点

  • 腹膜透析患者新发糖尿病汇总发生率为8%,糖耐量受损为15%,空腹血糖受损为32%。
  • 腹膜透析与血液透析的新发糖尿病风险无显著差异。
  • 新发糖尿病与腹膜透析患者死亡风险增加相关。

核心结论

  • 约半数腹膜透析患者可能发生糖代谢紊乱,且新发糖尿病可显著增加死亡风险。

主要发现

  • 新发糖尿病汇总发生率为8%(95%CI 4-12;I2=98%)。
  • 新发糖耐量受损汇总发生率为15%(95%CI 3-31;I2=97%),新发空腹血糖受损为32%(95%CI 27-37)。
  • 腹膜透析与血液透析的新发糖尿病风险无显著差异(RR 0.99,95%CI 0.69-1.40;P=0.94;I2=92%)。
  • 新发糖尿病与腹膜透析患者死亡风险增加相关(HR 1.06,95%CI 1.01-1.44;P<0.001;I2=92.5%)。

临床怎么用

  • 建议对腹膜透析患者常规进行葡萄糖耐量试验以筛查糖代谢紊乱。

局限性

  • 风险因素分析未得出明确结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peritoneal dialysis (PD) patients are at high risk of developing glucose metabolism disturbance (GMD). The incidence and prevalence of new-onset GMD, including diabetes mellitus (DM), impaired glucose tolerance (IGT) and impaired fast glucose (IFG), after initiation of PD, as well as their correlated influence factors, varies among studies in different areas and of different sample sizes. Also, the difference compared with hemodialysis (HD) remained unclear. Thus we designed this meta-analysis and systematic review to provide a full landscape of the occurrence of glucose disorders in PD patients. METHODS: We searched the MEDLINE, Embase, Web of Science and Cochrane Library databases for relevant studies through September 2018. Meta-analysis was performed on outcomes using random effects models with subgroup analysis and sensitivity analysis. RESULTS: We identified 1124 records and included 9 studies involving 13 879 PD patients. The pooled incidence of new-onset DM (NODM) was 8% [95% confidence interval (CI) 4-12; I2 = 98%] adjusted by sample sizes in PD patients. Pooled incidence rates of new-onset IGT and IFG were 15% (95% CI 3-31; I2 = 97%) and 32% (95% CI 27-37), respectively. There was no significant difference in NODM risk between PD and HD [risk ratio 0.99 (95% CI 0.69-1.40); P = 0.94; I2 = 92%]. PD patients with NODM were associated with an increased risk of mortality [hazard ratio 1.06 (95% CI 1.01-1.44); P < 0.001; I2 = 92.5%] compared with non-DM PD patients. CONCLUSIONS: Around half of PD patients may develop a glucose disorder, which can affect the prognosis by significantly increasing mortality. The incidence did not differ among different ethnicities or between PD and HD. The risk factor analysis did not draw a definitive conclusion. The glucose tolerance test should be routinely performed in PD patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Xue C, Gu YY, Cui CJ, et al. New-onset glucose disorders in peritoneal dialysis patients: a meta-analysis and systematic review. Nephrol Dial Transplant. 2020. PMID: 31236586. doi:10.1093/ndt/gfz116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。